209 related articles for article (PubMed ID: 16954722)
41. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
von Hentig N; Kaykhin P; Stephan C; Babacan E; Stürmer M; Staszewski S; Lötsch J
Antimicrob Agents Chemother; 2008 Jun; 52(6):2273-5. PubMed ID: 18411323
[TBL] [Abstract][Full Text] [Related]
42. Insulin sensitivity is preserved despite disrupted endothelial function.
Shankar SS; Considine RV; Gorski JC; Steinberg HO
Am J Physiol Endocrinol Metab; 2006 Oct; 291(4):E691-6. PubMed ID: 16705064
[TBL] [Abstract][Full Text] [Related]
43. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
Sahloff EG; Duggan JM
Ann Pharmacother; 2006 Oct; 40(10):1731-6. PubMed ID: 16968825
[TBL] [Abstract][Full Text] [Related]
44. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
[TBL] [Abstract][Full Text] [Related]
45. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
46. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
[TBL] [Abstract][Full Text] [Related]
47. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
Busti AJ; Bedimo R; Margolis DM; Hardin DS
J Investig Med; 2008 Feb; 56(2):539-44. PubMed ID: 18317438
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
49. The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese.
Syvertsen C; Halse J; Høivik HO; Gaullier JM; Nurminiemi M; Kristiansen K; Einerhand A; O'Shea M; Gudmundsen O
Int J Obes (Lond); 2007 Jul; 31(7):1148-54. PubMed ID: 17031391
[TBL] [Abstract][Full Text] [Related]
50. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
51. HIV protease inhibitors activate the adipocyte renin angiotensin system.
Boccara F; Auclair M; Cohen A; Lefèvre C; Prot M; Bastard JP; Capeau J; Caron-Debarle M
Antivir Ther; 2010; 15(3):363-75. PubMed ID: 20516556
[TBL] [Abstract][Full Text] [Related]
52. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.
Hogeland GW; Swindells S; McNabb JC; Kashuba AD; Yee GC; Lindley CM
Clin Pharmacol Ther; 2007 Jan; 81(1):69-75. PubMed ID: 17186001
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
Peng JZ; Pulido F; Causemaker SJ; Li J; Lorenzo A; Cepeda C; García Cabanillas JA; DaSilva B; Brun SC; Arribas J
J Clin Pharmacol; 2006 Mar; 46(3):265-74. PubMed ID: 16490802
[TBL] [Abstract][Full Text] [Related]
55. The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes.
Grigem S; Fischer-Posovszky P; Debatin KM; Loizon E; Vidal H; Wabitsch M
Horm Metab Res; 2005 Oct; 37(10):602-9. PubMed ID: 16278782
[TBL] [Abstract][Full Text] [Related]
56. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages.
Lagathu C; Eustace B; Prot M; Frantz D; Gu Y; Bastard JP; Maachi M; Azoulay S; Briggs M; Caron M; Capeau J
Antivir Ther; 2007; 12(4):489-500. PubMed ID: 17668557
[TBL] [Abstract][Full Text] [Related]
57. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Keiser PH; Nassar N
Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
[TBL] [Abstract][Full Text] [Related]
58. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
[TBL] [Abstract][Full Text] [Related]
59. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation.
Schonder KS; Shullo MA; Okusanya O
Ann Pharmacother; 2003 Dec; 37(12):1793-6. PubMed ID: 14632538
[TBL] [Abstract][Full Text] [Related]
60. Effects of lopinavir-ritonavir combined therapy during the rat pregnancy. Morphological and biochemical aspects.
Cunha AM; Hagemann CC; Simões RS; Oliveira-Filho RM; Simões MJ; Soares JM; Maciel GA; Oliveira FH; Amed AA; Kulay L
Eur J Obstet Gynecol Reprod Biol; 2007 Jul; 133(1):60-3. PubMed ID: 16989938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
